KBI Biopharma, Inc., a cGMP-compliant Contract Development and Manufacturing Organization of JSR Life Sciences ). Manufacturing Services, Inc. is a cGMP compliant Contract Manufacturing Organization serving the biopharmaceutical and diagnostics industries. The two parties announced a strategic alliance to provide biopharmaceutical customers with end-to-end drug substance and drug product manufacturing solutions. The arrangement combines KBI’s premier drug development and biologics manufacturing services with Argonaut’s expertise in aseptic fill-closure, resulting in a seamless integration of drug substance and drug product manufacturing. This alliance reinforces both companies’ commitment to supporting customers in bringing clinical and commercial therapies to patients quickly, safely and efficiently.
Biopharmaceutical companies are expected to benefit from this strategic collaboration through accelerated timelines and scalable manufacturing capabilities provided by both organizations.
J.D. Mowery, President and CEO of KBI Biopharma, said: “At KBI Biopharma, we are committed to delivering innovative solutions to accelerate the development and production of life-saving therapies. Our advanced facilities and world-class team have been expanding the scope of biopharmaceutical development. The frontier of possibility.”
Also Read : PacBio Announces New Nanobind PanDNA Kit Enabling HiFi Optimized DNA Extraction Solutions
He continued, “Similarly, Argonaut has established itself as a trusted supplier to the industry, known for its cutting-edge technology and track record of excellence in the production of pharmaceutical products. Their commitment to quality and efficiency aligns with our values and vision Absolutely. This collaboration represents a new era of collaboration and innovation in the biopharmaceutical industry.”
Wayne Woodard, founder and CEO of Argonaut, said: “We believe this strategic alliance solves a critical problem for biopharmaceutical companies because it greatly improves the coordination and coordination between two complex and critical aspects of drug development and manufacturing. Integration. Biopharmaceutical companies will benefit from an integrated solution that is faster, more flexible and leverages the unique expertise of both our companies. Argonaut’s fill-and-close capabilities can be expanded from rare disease drugs for first-in-human trials to Commercial production of approved products. Through this collaboration, biopharmaceutical companies can now smoothly move from development to full production, saving time and capital expenditures.”
In January 2023, Argonaut announced a capital investment focused on significantly expanding its production facility in Carlsbad, California, to increase capacity and scale. This partnership agreement with KBI further strengthens its commitment to continued growth.
SOURCE : BusinessWire